Little Deirdre Therese, Ward Harvey Rodrick Grenville
Bellingen District Hospital, Bellingen, New South Wales, Australia.
University of New South Wales, Coffs Harbour, New South Wales, Australia.
J Investig Med High Impact Case Rep. 2014 Oct 28;2(4):2324709614556129. doi: 10.1177/2324709614556129. eCollection 2014 Oct-Dec.
Three young women who developed premature ovarian insufficiency following quadrivalent human papillomavirus (HPV) vaccination presented to a general practitioner in rural New South Wales, Australia. The unrelated girls were aged 16, 16, and 18 years at diagnosis. Each had received HPV vaccinations prior to the onset of ovarian decline. Vaccinations had been administered in different regions of the state of New South Wales and the 3 girls lived in different towns in that state. Each had been prescribed the oral contraceptive pill to treat menstrual cycle abnormalities prior to investigation and diagnosis. Vaccine research does not present an ovary histology report of tested rats but does present a testicular histology report. Enduring ovarian capacity and duration of function following vaccination is unresearched in preclinical studies, clinical and postlicensure studies. Postmarketing surveillance does not accurately represent diagnoses in adverse event notifications and can neither represent unnotified cases nor compare incident statistics with vaccine course administration rates. The potential significance of a case series of adolescents with idiopathic premature ovarian insufficiency following HPV vaccination presenting to a general practice warrants further research. Preservation of reproductive health is a primary concern in the recipient target group. Since this group includes all prepubertal and pubertal young women, demonstration of ongoing, uncompromised safety for the ovary is urgently required. This matter needs to be resolved for the purposes of population health and public vaccine confidence.
三名在接种四价人乳头瘤病毒(HPV)疫苗后出现卵巢早衰的年轻女性前往澳大利亚新南威尔士州农村的一名全科医生处就诊。这三名互不相关的女孩确诊时年龄分别为16岁、16岁和18岁。她们在卵巢功能衰退开始之前均接种了HPV疫苗。疫苗接种在新南威尔士州的不同地区进行,这三名女孩生活在该州的不同城镇。在进行调查和诊断之前,她们每人都曾被开口服避孕药来治疗月经周期异常。疫苗研究没有提供受试大鼠的卵巢组织学报告,但提供了睾丸组织学报告。疫苗接种后卵巢的持久功能和功能持续时间在临床前研究、临床研究和上市后研究中均未得到研究。上市后监测在不良事件报告中不能准确体现诊断情况,既无法反映未报告的病例,也无法将事件统计数据与疫苗接种率进行比较。一系列HPV疫苗接种后出现特发性卵巢早衰的青少年病例的潜在意义值得进一步研究。生殖健康的保护是目标接种人群的首要关注点。由于该人群包括所有青春期前和青春期的年轻女性,因此迫切需要证明疫苗对卵巢的安全性持续且未受损害。为了公众健康和公众对疫苗的信心,这个问题需要得到解决。